ClinicalTrials.gg
CompletedNCT00684567Updated Jun 7, 2017Results posted

Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)

A Phase 2 interventional study of Radiotherapy and Temozolomide in Glioblastoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Sep 2005, registered May 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
134th of 221
30 · median 41
Started
2005
with 15 others
Phase 2
99 of 232
13 open now
Registered
79th of 232
by date
Lead sponsor
4 of 232
Merck Sharp & Dohme LLC

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 134th largest by enrollment of the 221 interventional ones that give a count, is one of 16 that started in 2005, is one of 99 in phase 2, and was the 79th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of combination therapy of radiotherapy and temozolomide ("concomitant radiotherapy phase"), and then temozolomide monotherapy ("monotherapy phase"), in patients with newly diagnosed glioblastoma multiforme. Progression free survival and response rate will also be calculated.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed newly diagnosed glioblastoma multiforme with WHO grade IV.
  • Histological diagnosis must be made locally after or neurosurgical tumor resection.
  • Four or more unstained tissue sections or a paraffin block must be provided to the Pathological Judgment Committee as tissue specimens.
  • Initial surgery/biopsy at diagnosis performed \<=6 weeks (42 days) prior to treatment with temozolomide.
  • Age: >=18 and \<=70 years.
  • performance status \<=2.
  • Stable, non-increasing dose of over the 14 days prior to treatment with temozolomide.
  • No prior chemotherapy or radiotherapy.
  • Laboratory test values obtained within 14 days before initiation of administration of temozolomide must satisfy the following criteria:

    • >= 1500/mm\^3;
    • count >= 100,000/mm\^3;
    • serum creatinine \<=1.5 times the upper limit of laboratory normal;
    • total \<=1.5 times the upper limit of laboratory normal;
    • glutamic oxaloacetic transaminase or glutamic pyruvic transaminase \<2.5 times the upper limit of laboratory normal;
    • alkaline phosphatase \< 2.5 times the upper limit of laboratory normal.
  • Absence of pathological conditions that interfere with taking oral drugs.
  • during the study period (from to the day of the last observation/examination of this study) is required in sexually active, potentially fertile patients, regardless of sex, under the supervision of the investigator or sub-investigator.
  • The investigator and/or subinvestigator must judge that is 12 weeks or more.
  • Patients may be included regardless of sex or inpatient/outpatient.

Exclusion criteria

Exclusion Criteria:

  • Extensively disseminated glioblastoma multiforme.
  • Severe disorders in the heart, liver, kidney, blood, etc.
  • Presence of previous or concurrent at other sites with the exception of surgically cured carcinoma in-situ of the cervix and non melanoma skin cancer.
  • Women who are pregnant or lactating.
  • Women who may be pregnant or who could become pregnant and do not adopt method(s).
  • Participation in another clinical study within 6 weeks prior to the initiation of administration of temozolomide.
  • Subjects who the investigator and/or subinvestigator judged inappropriate to participate in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Single arm

    It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.

    Radiation: Radiotherapy · Drug: Temozolomide

Interventions

  • RadiationRadiotherapy

    Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.

    Also known as: Irradiation, radiation therapy

  • During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.

    Also known as: Temodal, Temodar, SCH 052365

06

What researchers measure

Primary outcomes

  1. Adverse Events With an Incidence of Greater Than or Equal to 20%

    Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy. Adverse events were classified under the system organ class using MedDRA-J Version 11.0.

    Time frame: until 30 days after the completion of administration of monotherapy

  2. Adverse Drug Reactions With an Incidence of Greater Than or Equal to 20%

    Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy.

    Time frame: until 30 days after the completion of administration of monotherapy

  3. Abnormal Changes in Laboratory Test Values With an Incidence of Greater Than or Equal to 20%

    Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy.

    Time frame: until 30 days after the completion of administration of monotherapy

Secondary outcomes

  1. Number of Participants With Progression Free Survival (PFS) for 1 Year

    Administration of SCH 52365 was continued until progression was observed (progression was judged by the investigator based on MRI and clinical symptoms).

    Time frame: 1 year after the start of admininstration in the concomitant radiotherapy phase

  2. Number of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response

    CR = measurable lesion disappeared. PR = total sum of lesions measurable in bidimension decreased by 50% or more on whole and no secondary progression attributable to tumor was noted. No onset of new lesion.

    Time frame: 1 year after the start of administration in the concomitant radiotherapy phase

07

Results

Posted Mar 12, 2009

Participant flow

Concomitant Radiotherapy Period
Participant flow — Concomitant Radiotherapy Period
MilestoneRadiotherapy/Temozolomide
Started30
Completed28
Not completed2
Withdrew: Adverse event2
Monotherapy Period
Participant flow — Monotherapy Period
MilestoneRadiotherapy/Temozolomide
Started23
Completed9
Not completed14
Withdrew: Adverse event2
Withdrew: Death1
Withdrew: Progression of primary disease11

Outcome measures

PrimaryAdverse Events With an Incidence of Greater Than or Equal to 20%

Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy. Adverse events were classified under the system organ class using MedDRA-J Version 11.0.

Time frame:
until 30 days after the completion of administration of monotherapy
Reported as:
Number · Participants
Adverse Events With an Incidence of Greater Than or Equal to 20%
ParticipantsRadiotherapy/Temozolomide
alopecia25
nausea17
anorexia17
constipation15
malaise14
rash11
weight decreased11
headache10
vomiting9
dry skin8
nasopharyngitis8
diarrhea7
convulsion7
pruritus6
neutrophil count decreased6
wound complication6
PrimaryAdverse Drug Reactions With an Incidence of Greater Than or Equal to 20%

Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy.

Time frame:
until 30 days after the completion of administration of monotherapy
Reported as:
Number · Participants
Adverse Drug Reactions With an Incidence of Greater Than or Equal to 20%
ParticipantsRadiotherapy/Temozolomide
constipation15
nausea11
vomiting6
neutrophil count decreased6
weight decreased6
malaise7
anorexia9
PrimaryAbnormal Changes in Laboratory Test Values With an Incidence of Greater Than or Equal to 20%

Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy.

Time frame:
until 30 days after the completion of administration of monotherapy
Reported as:
Number · Participants
Abnormal Changes in Laboratory Test Values With an Incidence of Greater Than or Equal to 20%
ParticipantsRadiotherapy/Temozolomide
lymphocyte count decreased24
white blood cell count decreased14
eosinophil percentage increased10
SecondaryNumber of Participants With Progression Free Survival (PFS) for 1 Year

Administration of SCH 52365 was continued until progression was observed (progression was judged by the investigator based on MRI and clinical symptoms).

Time frame:
1 year after the start of admininstration in the concomitant radiotherapy phase
Reported as:
Number · Participants
Number of Participants With Progression Free Survival (PFS) for 1 Year
ParticipantsRadiotherapy/Temozolomide
Number of Participants With Progression Free Survival (PFS) for 1 Year11 (20.1 to 53.4)
SecondaryNumber of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response

CR = measurable lesion disappeared. PR = total sum of lesions measurable in bidimension decreased by 50% or more on whole and no secondary progression attributable to tumor was noted. No onset of new lesion.

Time frame:
1 year after the start of administration in the concomitant radiotherapy phase
Reported as:
Number · Participants
Number of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response
ParticipantsRadiotherapy/Temozolomide
Number of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response6 (12.6 to 56.6)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Radiotherapy/Temozolomide—13/30 (43.3%)30/30 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRadiotherapy/Temozolomide
CONVULSIONNervous system disorders2/30
EPILEPSYNervous system disorders2/30
CARDIO-RESPIRATORY ARRESTCardiac disorders1/30
NECROSISGeneral disorders1/30
PNEUMONIAInfections and infestations1/30
LYMPHOCYTE COUNT DECREASEDInvestigations1/30
NEUTROPHIL COUNT DECREASEDInvestigations1/30
GASTRIC CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30
METASTASISNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30
ALTERED STATE OF CONSCIOUSNESSNervous system disorders1/30
Most frequent other events
Showing 10 of 71
Most frequent other events
EventRadiotherapy/Temozolomide
LYMPHOCYTE COUNT DECREASEDInvestigations25/30
ALOPECIASkin and subcutaneous tissue disorders25/30
NAUSEAGastrointestinal disorders17/30
ANOREXIAMetabolism and nutrition disorders17/30
CONSTIPATIONGastrointestinal disorders15/30
MALAISEGeneral disorders14/30
WHITE BLOOD CELL COUNT DECREASEDInvestigations14/30
WEIGHT DECREASEDInvestigations11/30
RASHSkin and subcutaneous tissue disorders11/30
EOSINOPHIL PERCENTAGE INCREASEDInvestigations10/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Radiotherapy/Temozolomide
Mean54.2 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Radiotherapy/Temozolomide
Female16
Male14
Centralized Pathologic Diagnosis
Centralized Pathologic Diagnosis(Participants)Radiotherapy/Temozolomide
High Grade Astrocytoma1
Glioblastoma Multiforme27
Anaplastic Astrocytoma1
Gliosarcoma1
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Radiotherapy/Temozolomide
014
111
25
30
40
50
Type of Surgery
Type of Surgery(Participants)Radiotherapy/Temozolomide
Radical Extraction7
Partial Extraction21
Biopsy2
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2005 to primary completion in Oct 2007, 25 months.

Results were first posted in Mar 2009, 1 year 4 months after primary completion.

Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's 25 months is below that.

Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2008
First posted
May 26, 2008
StartActual
Sep 27, 2005
Primary completionActual
Oct 31, 2007
CompletionActual
Oct 31, 2007
Results first posted
Mar 12, 2009
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00684567
Responsible party
Sponsor
First posted
May 26, 2008
Start date
Sep 27, 2005
Primary completion
Oct 31, 2007
Completion
Oct 31, 2007
Results posted
Mar 12, 2009
Last update
Jun 7, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion